Hydrogen gas therapy induced shrinkage of metastatic gallbladder cancer: A case report
Chen JB, Pan ZB, Du DM, Qian W, Ma YY, Mu F, Xu KC. · World journal of clinical cases. 2019;7(15):2065-2074.
Study at a glance
Human
Human participants studied for cancer research. See eligibility criteria in the linked full text.
Full text reports inhaled H₂-containing gas. Detected intervention quantities or schedules: 3 L/min, 67%, 33%, 37%, 6%. · H₂-related quantities reported in the intervention passages: 3 L/min, 67%, 33%, 37%, 6%. Values are not combined across different experimental arms.
3 L/min
Article-reported result excerpt (24 words maximum): “The frequency of transfusions was decreased gradually after hydrogen therapy and stopped completely after 2 mo of treatment..” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
Human evidence; design, sample size and comparator limit interpretation. No funding statement was identified in the machine-readable full article; absence is not inferred. The article declares no conflicts of interest.
What kind of evidence is this?
Human
Case report
Cancer research
Inhaled H₂
Information not yet classified
Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.
Methods
Human participants studied for cancer research. See eligibility criteria in the linked full text.
Human study; the article does not state one consolidated sample total, so no total is inferred.
3 L/min
Full text reports inhaled H₂-containing gas. Detected intervention quantities or schedules: 3 L/min, 67%, 33%, 37%, 6%.
Brown’s gas / oxyhydrogen — H₂ and O₂ co-delivered, not H₂ alone.
H₂-related quantities reported in the intervention passages: 3 L/min, 67%, 33%, 37%, 6%. Values are not combined across different experimental arms.
2010 mL/min H₂, calculated from 67% H₂ and 3000 mL/min total flow reported in the full text.
33% O₂; 990 mL/min O₂ calculated from the reported total flow.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “The frequency of transfusions was decreased gradually after hydrogen therapy and stopped completely after 2 mo of treatment..” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Human evidence; design, sample size and comparator limit interpretation. No funding statement was identified in the machine-readable full article; absence is not inferred. The article declares no conflicts of interest.
Applies only to the population and protocol reported in this cancer research article.
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 31423439 · DOI: 10.12998/wjcc.v7.i15.2065
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
10 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.